VYZULTA

This brand name is authorized in Brazil, Canada, Hong Kong, Turkey, United States

Active ingredients

The drug VYZULTA contains one active pharmaceutical ingredient (API):

1 Latanoprostene bunod UNII I6393O0922 - LATANOPROSTENE BUNOD

Latanoprostene bunod is thought to lower intraocular pressure by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Intraocular pressure is a major modifiable risk factor for glaucoma progression. Reduction of intraocular pressure reduces risk of glaucomatous visual field loss. Read about Latanoprostene bunod

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
VYZULTA Οphthalmic solution	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
S01EE06		S Sensory organs → S01 Ophthalmologicals → S01E Antiglaucoma preparations and miotics → S01EE Prostaglandin analogues
Discover more medicines within S01EE06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 503121080003002, 503121080003102
Country: CA	Health Products and Food Branch	Identifier(s): 02484218
Country: HK	Department of Health Drug Office	Identifier(s): 66408
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8681738610048
Country: US	FDA, National Drug Code	Identifier(s): 24208-504